• Matthew Singh will lead the go-to-market branding and sales strategy for Psyched Wellness’ AME-1 derived products
  • He is currently the head of VPX Pharmaceuticals’ numerous CPG properties in Canada
  • Mr. Singh spent almost a decade at Red Bull Canada, where he ran the company’s Business Development department
  • Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products
  • Psyched Wellness (PSYC) opened trading at C$0.225 per share

Psyched Wellness is pleased to welcome Matthew Singh as a consultant to lead the go-to-market branding and sales strategy for its AME-1 derived products.

Mr. Singh has a proven track record of success launching brands, products, departments, and national business units within the multibillion-dollar beverage and pharmaceutical industries.

He is currently the head of VPX Pharmaceuticals’ numerous CPG properties in Canada, where he has secured immediate profitability for each new Sports Nutrition, Energy Drink, Cannabis, and Alcoholic good VPX launched.

Prior to VPX, Mr. Singh spent almost a decade at Red Bull Canada, where he ran the company’s Business Development department and spent over seven years with Coca-Cola.

He has been an integral contributor for multiple start-up entities as a consultant, board member and board strategic advisor within the Health and Wellness, and Digital Intelligence verticals.

Mr. Singh stated,

“I have been fortunate to work with industry leaders and market disruptors in the extremely competitive beverage and pharmaceutical landscapes and I can confidently say the CPG potential being developed by the team at Psyched Wellness has me more excited than anything I have witnessed in my career thus far.

We truly believe this product will have a sustainable commercial and societal impact, starting in North America and then scaling up globally. I believe Amanita will change the world with its power to help stress relief, relaxation, assist with restful sleeping, and I am proud to be a part of the journey. My thanks to Jeff, David, and the Board for adding me to an already stellar team,” Mr. Singh said.

Jeff Stevens, CEO of Psyched said,

“We are thrilled to have Matt join the team at Psyched Wellness to drive our branding and sales strategy. He brings an invaluable amount of experience and expertise in all things CPG, and he will be integral in driving the continual development of the company’s go-to-market strategy.

We are on track to file our application with the FDA for a New Dietary Ingredient (NDI) and Health Canada for a Natural Health Product Number (NHPN) in December 2021, when the pre-clinical trials are completed. This positions Psyched Wellness to be able to begin marketing products in both countries in the first half of 2022. Initiating the branding and marketing strategy now affords us enough time to hit the ground running in the first half of 2022,” said Jeff Stevens, CEO of Psyched Wellness.

Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Psyched Wellness Ltd. (PSYC) opened trading at C$0.225 per share.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.